Glenmark Pharmaceuticals Limited (Glenmark) has received final FDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, the generic version of Pfizer Inc.’s Cleocin® Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg. Glenmark Pharmaceuticals Inc., USA will distribute Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg in the United States.
The Cleocin® Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg market2 achieved annual sales of approximately $33.6 million*, according to IQVIATM sales data for the 12-month period ending January 2023.
Glenmark’s current portfolio includes 181 products that are authorised for distribution in the United States, as well as 47 ANDAs that are awaiting FDA approval. Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, in addition to these internal filings.